Trial Profile

A Second Clinical Trial to Evaluate Temozolomide (Kimozo) in Pediatric Patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Temozolomide (Primary)
Indications Neuroblastoma
Focus Adverse reactions
Sponsors ORPHELIA Pharma

Most Recent Events

09 Oct 2020 New trial record
05 Oct 2020 According to an ORPHELIA Pharma media release, the company is now preparing the opening of the second clinical trial, which will evaluate Kimozo in pediatric patients, by the end of the year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com